These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
369 related articles for article (PubMed ID: 20533592)
21. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype. Judson IR J Clin Oncol; 2008 Nov; 26(33):5322-5. PubMed ID: 18955449 [No Abstract] [Full Text] [Related]
22. Novel approaches to imatinib- and sunitinib-resistant GIST. Reichardt P Curr Oncol Rep; 2008 Jul; 10(4):344-9. PubMed ID: 18778561 [TBL] [Abstract][Full Text] [Related]
23. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. Liegl B; Kepten I; Le C; Zhu M; Demetri GD; Heinrich MC; Fletcher CD; Corless CL; Fletcher JA J Pathol; 2008 Sep; 216(1):64-74. PubMed ID: 18623623 [TBL] [Abstract][Full Text] [Related]
24. Beyond imatinib: second generation c-KIT inhibitors for the management of gastrointestinal stromal tumors. von Mehren M Clin Colorectal Cancer; 2006 Nov; 6 Suppl 1():S30-4. PubMed ID: 17419150 [TBL] [Abstract][Full Text] [Related]
25. [Molecular mechanism and therapeutic strategy for resistance to tyrosine kinase inhibitors in targeted treatment of gastrointestinal stromal tumors]. Xu J; Cao H Zhonghua Wei Chang Wai Ke Za Zhi; 2013 Mar; 16(3):288-91. PubMed ID: 23536353 [TBL] [Abstract][Full Text] [Related]
26. Molecular pathobiology of gastrointestinal stromal sarcomas. Corless CL; Heinrich MC Annu Rev Pathol; 2008; 3():557-86. PubMed ID: 18039140 [TBL] [Abstract][Full Text] [Related]
32. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib]. Hong JL; Li J; Li J; Shen L Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406 [TBL] [Abstract][Full Text] [Related]
33. Molecular research directions in the management of gastrointestinal stromal tumors. Tarn C; Godwin AK Curr Treat Options Oncol; 2005 Nov; 6(6):473-86. PubMed ID: 16242052 [TBL] [Abstract][Full Text] [Related]
34. Molecular analysis of secondary kinase mutations in imatinib-resistant gastrointestinal stromal tumors. Lim KH; Huang MJ; Chen LT; Wang TE; Liu CL; Chang CS; Liu MC; Hsieh RK; Tzen CY Med Oncol; 2008; 25(2):207-13. PubMed ID: 18488160 [TBL] [Abstract][Full Text] [Related]
38. Combined treatment strategies in gastrointestinal stromal tumors (GISTs) after imatinib and sunitinib therapy. Pantaleo MA; Nannini M; Di Battista M; Catena F; Biasco G Cancer Treat Rev; 2010 Feb; 36(1):63-8. PubMed ID: 19914780 [TBL] [Abstract][Full Text] [Related]
39. Hits and misses in targeting pediatric cancers. Bernstein ML Pediatr Blood Cancer; 2009 Jul; 52(7):751-2. PubMed ID: 19185009 [No Abstract] [Full Text] [Related]
40. Gastrointestinal stromal tumors, version 2.2014. von Mehren M; Randall RL; Benjamin RS; Boles S; Bui MM; Casper ES; Conrad EU; DeLaney TF; Ganjoo KN; George S; Gonzalez RJ; Heslin MJ; Kane JM; Mayerson J; McGarry SV; Meyer C; O'Donnell RJ; Pappo AS; Paz IB; Pfeifer JD; Riedel RF; Schuetze S; Schupak KD; Schwartz HS; Van Tine BA; Wayne JD; Bergman MA; Sundar H J Natl Compr Canc Netw; 2014 Jun; 12(6):853-62. PubMed ID: 24925196 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]